Exicure, Inc. (NASDAQ:XCUR) stock is trading higher on Tuesday. Its session volume was 13.62 million, compared with the average volume of 151.41 thousand, according to data from Benzinga Pro.The company shared results from its Phase 2 trial of burixafor (GPC-100) in combination with propranolol and granulocyte colony-stimulating factor (G-CSF) for the mobilization of hematopoietic progenitor cells (HPCs) in multiple myeloma patients undergoing autologous hematopoietic cell transplantation.The data showed th ...

Exicure (NASDAQ: XCUR), a clinical-stage biotechnology company specializing in next-generation stem-cell mobilization therapies, has staged a massive rally as investors reacted to the company’s new breakthrough products.Ahead of the market open on December 9, XCUR shares surged 70% in pre-market trading to about $9. The spike followed months of steep declines, with the stock closing the previous session at $5.33, down 64.89% year to date.Exicure YTD stock price chart. Source: Google Finance The early-mornin ...